LT4273241T - Labai stipriai veikianti rūgštinė alfa-gliukosidazė, pasižyminti didesniu angliavandenių kiekiu - Google Patents

Labai stipriai veikianti rūgštinė alfa-gliukosidazė, pasižyminti didesniu angliavandenių kiekiu

Info

Publication number: LT4273241T
Authority: LT; Lithuania
Prior art keywords: glucosidase; acid alpha; higher carbohydrates; powerful acid; powerful
Prior art date: 2014-09-30

Application number

LTEP23191307.0T

Other languages

English (en)

Inventor

Russell GOTSCHALL

Hung Do

Original Assignee

Amicus Therapeutics, Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-09-30

Filing date

2015-09-30

Publication date

2025-02-10

2015-09-30 Application filed by Amicus Therapeutics, Inc. filed Critical Amicus Therapeutics, Inc.

2025-02-10 Publication of LT4273241T publication Critical patent/LT4273241T/lt

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2465—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/0102—Alpha-glucosidase (3.2.1.20)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Genetics & Genomics (AREA)
General Health & Medical Sciences (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Medicinal Chemistry (AREA)
General Engineering & Computer Science (AREA)
Biochemistry (AREA)
Biotechnology (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Microbiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Diabetes (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
Biophysics (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Hematology (AREA)
Obesity (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Oil, Petroleum & Natural Gas (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Enzymes And Modification Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

LTEP23191307.0T 2014-09-30 2015-09-30 Labai stipriai veikianti rūgštinė alfa-gliukosidazė, pasižyminti didesniu angliavandenių kiekiu LT4273241T (lt)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date
US201462057847P	2014-09-30	2014-09-30
US201462057842P	2014-09-30	2014-09-30
US201562112463P	2015-02-05	2015-02-05
US201562135345P	2015-03-19	2015-03-19

Publications (1)

Publication Number	Publication Date
LT4273241T true LT4273241T (lt)	2025-02-10

Family

ID=55631441

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
LTEP23191307.0T LT4273241T (lt)	2014-09-30	2015-09-30	Labai stipriai veikianti rūgštinė alfa-gliukosidazė, pasižyminti didesniu angliavandenių kiekiu
LTEPPCT/US2015/053252T LT3201320T (lt)	2014-09-30	2015-09-30	Didelio aktyvumo rūgštinė alfa-gliukozidazė su sustiprintais karbohidratais
LTPA2024509C LTPA2024509I1 (lt)	2014-09-30	2024-04-02
LTPA2025521C LTPA2025521I1 (lt)	2014-09-30	2025-06-02

Family Applications After (3)

Application Number	Title	Priority Date	Filing Date
LTEPPCT/US2015/053252T LT3201320T (lt)	2014-09-30	2015-09-30	Didelio aktyvumo rūgštinė alfa-gliukozidazė su sustiprintais karbohidratais
LTPA2024509C LTPA2024509I1 (lt)	2014-09-30	2024-04-02
LTPA2025521C LTPA2025521I1 (lt)	2014-09-30	2025-06-02

Country Status (39)

Country	Link
US (6)	US10208299B2 (lt)
EP (3)	EP4273241B1 (lt)
JP (3)	JP6851964B2 (lt)
KR (4)	KR102741048B1 (lt)
CN (2)	CN107075468B (lt)
AU (3)	AU2015325028B2 (lt)
BR (1)	BR112017005810A2 (lt)
CA (2)	CA2961762C (lt)
CL (1)	CL2017000722A1 (lt)
CO (1)	CO2017002776A2 (lt)
CR (1)	CR20170107A (lt)
CY (2)	CY1126544T1 (lt)
DK (2)	DK3201320T5 (lt)
DO (1)	DOP2017000079A (lt)
EA (1)	EA038986B1 (lt)
EC (1)	ECSP17019103A (lt)
ES (2)	ES3017134T3 (lt)
FI (4)	FI4273241T3 (lt)
FR (2)	FR24C1012I1 (lt)
HR (2)	HRP20250058T1 (lt)
HU (4)	HUE064629T2 (lt)
IL (4)	IL307587A (lt)
LT (4)	LT4273241T (lt)
MX (2)	MX388241B (lt)
MY (1)	MY186336A (lt)
NI (1)	NI201700039A (lt)
NO (1)	NO2025023I1 (lt)
PE (1)	PE20170906A1 (lt)
PH (1)	PH12017500455A1 (lt)
PL (2)	PL4273241T3 (lt)
PT (2)	PT3201320T (lt)
RS (2)	RS66510B1 (lt)
SG (2)	SG11201702114TA (lt)
SI (2)	SI4273241T1 (lt)
SM (2)	SMT202400010T1 (lt)
SV (1)	SV2017005416A (lt)
TN (1)	TN2017000082A1 (lt)
WO (1)	WO2016054231A1 (lt)
ZA (2)	ZA201701945B (lt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR102741048B1 (ko)	2014-09-30	2024-12-11	아미쿠스 세라퓨틱스, 인코포레이티드	개선된 탄수화물을 가지는 고도로 강력한 산성 알파-글루코시다제
CA3010205A1 (en) *	2015-12-30	2017-07-06	Amicus Therapeutics, Inc.	Augmented acid alpha-glucosidase for the treatment of pompe disease
HUE054733T2 (hu) *	2015-12-30	2021-09-28	Amicus Therapeutics Inc	Megnövelt savas alfa-glükozidáz Pompe-kór kezelésére
TWI823272B (zh) *	2016-03-30	2023-11-21	美商阿米庫斯醫療股份有限公司	用於選擇高m6p重組蛋白之方法
MX2018011951A (es) *	2016-03-30	2019-02-13	Amicus Therapeutics Inc	Metodo para seleccionar proteinas recombinantes ricas en m6p.
KR20250017756A (ko)	2016-03-30	2025-02-04	아미쿠스 세라퓨틱스, 인코포레이티드	재조합 산 알파-글루코시다제를 포함하는 제형
TW201829770A (zh) *	2017-01-10	2018-08-16	美商阿米庫斯醫療股份有限公司	用於治療fabry氏病之重組α-半乳糖苷酶A
EA202290114A1 (ru) *	2017-03-30	2022-03-29	Амикус Терапьютикс, Инк.	Способ отбора рекомбинантных белков с высоким содержанием m6p
HRP20230576T1 (hr)	2017-05-15	2023-09-01	Amicus Therapeutics, Inc.	Rekombinantna ljudska kisela alfa-glukozidaza
US20220193250A1 (en)	2018-08-02	2022-06-23	Dyne Therapeutics, Inc.	Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US12018087B2 (en)	2018-08-02	2024-06-25	Dyne Therapeutics, Inc.	Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
WO2021046443A1 (en)	2019-09-06	2021-03-11	Amicus Therapeutics, Inc.	Method for capturing and purification of biologics
BR112023016212A2 (pt) *	2021-02-11	2023-11-28	Amicus Therapeutics Inc	Alfa-glucosidase ácida humana recombinante e usos da mesma
US20250134967A1 (en) *	2022-02-07	2025-05-01	M6P Therapeutics, Inc.	Compositions comprising acid alpha glucosidase and methods of use thereof
AU2023265155A1 (en) *	2022-05-05	2024-12-12	Amicus Therapeutics, Inc.	Methods for treating pompe disease
AU2023406510A1 (en) *	2022-12-02	2025-07-10	Amicus Therapeutics, Inc.	Fexamethods for treating infantile-onset pompe disease in pediatric patients
EP4626465A1 (en) *	2022-12-02	2025-10-08	Amicus Therapeutics, Inc.	Methods for treating late onset pompe disease in pediatric patients
WO2026006625A1 (en)	2024-06-26	2026-01-02	Amicus Therapeutics, Inc.	Miglustat formulations comprising nitrosamine for use in the treatment of pompe disease

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4837237A (en)	1985-07-09	1989-06-06	Fred Hutchinson Cancer Research Center	Therapy using glucosidase processing inhibitors
US5879680A (en)	1987-12-23	1999-03-09	The United States Of America As Represented By The Department Of Health And Human Services	Cloned DNA for synthesizing unique glucocerebrosidase
US4985445A (en)	1988-02-12	1991-01-15	Meiji Seika Kaisha, Ltd.	Cancer cell metastasis inhibitors and novel compounds
US6451600B1 (en)	1989-12-22	2002-09-17	Genzyme Corporation	Enzymatically active recombinant glucocerebrosidase
US5236838A (en)	1988-12-23	1993-08-17	Genzyme Corporation	Enzymatically active recombinant glucocerebrosidase
US5179023A (en)	1989-03-24	1993-01-12	Research Corporation Technologies, Inc.	Recombinant α-galactosidase a therapy for Fabry disease
US5011829A (en)	1989-06-02	1991-04-30	G. D. Searle & Co.	Pharmaceutical composition and method of inhibiting virus
US5103008A (en)	1989-08-17	1992-04-07	Monsanto Company	Compound, N-butyl-deoxynojirimycin-6-phosphate
US5401650A (en)	1990-10-24	1995-03-28	The Mount Sinai School Of Medicine Of The City University Of New York	Cloning and expression of biologically active α-galactosidase A
US5399567A (en)	1993-05-13	1995-03-21	Monsanto Company	Method of treating cholera
US6118045A (en)	1995-08-02	2000-09-12	Pharming B.V.	Lysosomal proteins produced in the milk of transgenic animals
US6458574B1 (en)	1996-09-12	2002-10-01	Transkaryotic Therapies, Inc.	Treatment of a α-galactosidase a deficiency
US6083725A (en)	1996-09-13	2000-07-04	Transkaryotic Therapies, Inc.	Tranfected human cells expressing human α-galactosidase A protein
US6210666B1 (en)	1997-10-21	2001-04-03	Orphan Medical, Inc.	Truncated α-galactosidase A to treat fabry disease
CA2309321A1 (en)	1997-11-10	1999-05-20	G.D. Searle & Co.	Use of alkylated iminosugars to treat multidrug resistance
US6465488B1 (en)	1997-12-11	2002-10-15	Chancellor, Masters & Scholars Of The University Of Oxford	Inhibition of glycolipid biosynthesis
US6274597B1 (en)	1998-06-01	2001-08-14	Mount Sinai School Of Medicine Of New York University	Method of enhancing lysosomal α-Galactosidase A
JP4990434B2 (ja)	1998-12-07	2012-08-01	ジェンザイム・コーポレーション	ポンペ病の処置
WO2000047198A2 (en)	1999-02-12	2000-08-17	G.D. Searle & Co.	Use of substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds for treating hepatitis virus infections
ATE234626T1 (de)	1999-07-26	2003-04-15	Searle & Co	Verwendung von langkettigen n-alkyl derivaten von deoxynojirimycin mit glucocerebrosidase enzyme zur herstellung eines medikaments zur behandlung von mit glykolipiden akkumulation zusammenhängenden krankheiten
US6534300B1 (en)	1999-09-14	2003-03-18	Genzyme Glycobiology Research Institute, Inc.	Methods for producing highly phosphorylated lysosomal hydrolases
US20040204379A1 (en)	2000-06-19	2004-10-14	Cheng Seng H.	Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
AU2001269923A1 (en)	2000-06-19	2002-01-02	Genzyme Corporation	Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
ES2523024T3 (es)	2000-07-18	2014-11-20	Duke University	Tratamiento de glucogenosis de tipo II
CN1638739A (zh)	2000-08-18	2005-07-13	法玛西雅厄普约翰美国公司	治疗成瘾性障碍的化合物
US7723296B2 (en)	2001-01-18	2010-05-25	Genzyme Corporation	Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
IL158623A0 (en)	2001-04-30	2004-05-12	Symbiontics Inc	Subcellular targeting of therapeutic proteins
US7560424B2 (en)	2001-04-30	2009-07-14	Zystor Therapeutics, Inc.	Targeted therapeutic proteins
JP2005523882A (ja)	2001-10-16	2005-08-11	アールエックスキネティックス，インコーポレイテッド	高濃度タンパク質製剤および製造の方法
US20030072761A1 (en)	2001-10-16	2003-04-17	Lebowitz Jonathan	Methods and compositions for targeting proteins across the blood brain barrier
US7658916B2 (en)	2002-04-05	2010-02-09	Genzyme Corporation	Methods of enhancing lysosomal storage disease therapy by modulation of cell surface receptor density
ES2545619T3 (es)	2003-01-31	2015-09-14	The Mount Sinai School Of Medicine Of New York University	Terapia de combinación para tratar trastornos de deficiencia de proteínas
FR2861991B1 (fr)	2003-11-07	2008-01-18	Centre Nat Rech Scient	Utilisation d'inhibiteurs de glucosidase pour une therapie de la mucoviscidose
AU2005211775B2 (en) *	2004-02-06	2009-10-08	Biomarin Pharmaceutical Inc.	Manufacture of highly phosphorylated lysosomal enzymes and uses thereof
EP1716232B9 (en)	2004-02-10	2010-10-13	ZyStor Therapeutics , Inc.	Acid alpha-glucosidase and fragments thereof
US20060142234A1 (en)	2004-12-23	2006-06-29	Guohua Chen	Injectable non-aqueous suspension
MX2007014470A (es)	2005-05-17	2008-02-06	Amicus Therapeutics Inc	Metodo para el tratamiento de enfermedad de pompe usando derivados de 1-desoxinojirimicina.
AU2007322123A1 (en)	2006-11-13	2008-05-29	Biomarin Pharmaceutical Inc.	Methods for treating Pompe disease
CN101636200A (zh) *	2006-11-13	2010-01-27	齐斯特治疗公司	用于治疗庞贝氏症的方法
WO2008112525A2 (en)	2007-03-09	2008-09-18	Link Medicine Corporation	Treatment of lysosomal storage diseases
CA2685332A1 (en)	2007-04-26	2008-11-06	Amicus Therapeutics, Inc.	Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
EP2252288A1 (en)	2007-11-21	2010-11-24	Summit Corporation Plc	Treatment of protein folding disorders
WO2009075815A1 (en)	2007-12-07	2009-06-18	Duke University	Immunomodulating gene therapy
DK2252313T3 (en)	2008-02-12	2015-07-13	Amicus Therapeutics Inc	METHOD TO PREDICT response to Pharmacological chaperone TREATMENT OF DISEASES
CA2718182A1 (en)	2008-03-12	2009-09-17	Amicus Therapeutics, Inc.	Treatment of pompe disease with specific pharmacological chaperones and monitoring treatment using surrogate markers
JP2011517556A (ja)	2008-03-12	2011-06-16	アミカスセラピューティックスインコーポレイテッド	ポンペ病のための治療選択肢を診断し評価するための検定
CA2723412A1 (en) *	2008-05-07	2009-11-12	Zystor Therapeutics, Inc.	Lysosomal targeting peptides and uses thereof
EP2323652A2 (en)	2008-08-06	2011-05-25	Summit Corporation Plc	Treatment of lysosomal storage disorders and other proteostatic diseases
US20100119502A1 (en)	2008-11-11	2010-05-13	Amicus Therapeutics, Inc.	Therapy regimens, dosing regimens and stable medicaments for the treatment of pompe disease
HUE060974T2 (hu)	2008-12-16	2023-04-28	Genzyme Corp	Szintetikus intermedierek oligoszacharid-fehérje konjugátumok elõállítására
US8466340B2 (en) *	2009-02-18	2013-06-18	Amicus Therapeutics, Inc.	Mouse model for pompe disease and methods of use thereof
ES2564093T3 (es)	2009-04-09	2016-03-17	Amicus Therapeutics, Inc.	Métodos para prevenir y/o tratar trastornos del almacenamiento lisosomal
EP2475376B1 (en)	2009-06-17	2016-03-30	BioMarin Pharmaceutical Inc.	Formulations for lysosomal enzymes
JP5415170B2 (ja)	2009-07-21	2014-02-12	富士フイルム株式会社	複眼撮像装置
CN104651428A (zh) *	2009-09-29	2015-05-27	根特大学	水解甘露糖-1-磷酸-6-甘露糖连接为磷酸-6-甘露糖
WO2011109600A1 (en)	2010-03-05	2011-09-09	Alnylam Pharmaceuticals, Inc.	Compositions and methods for modifying the glycosylation pattern of a polypeptide
JP6151183B2 (ja) *	2010-09-29	2017-06-21	オキシレインユーケーリミテッド	マンノース−１−ホスホ−６−マンノース結合からキャップを外すことおよびリン酸化ｎ−グリカンを脱マンノシル化することができるマンノシダーゼならびに哺乳動物細胞による糖タンパク質の取り込みを促進する方法
SG194486A1 (en)	2011-04-22	2013-12-30	Genzyme Corp	Modified acid alpha glucosidase with accelerated processing
BR112013030432A2 (pt) *	2011-05-27	2016-12-13	Callidus Biopharma Inc	método para preparar um peptídeo conjugado alvo para uma enzima lisossomal recombinante, método para preparar uma molécula para terapia de reposição de enzima, conjugado, método para tratar um indivíduo sofrendo de uma doença de armazenamento lisossomal, método para tratar um indivíduo sofrendo de uma doença de armazenamento lisossomal, método para tratar um paciente sofrendo da doença de pompe, doença de fabry, e doença de gaucher, mps i, mps ii, mps vii, tay sachs, sandhoff, alfa-manosidose, e wohlman, sequência de dna e sequência de aminoácidos
WO2013013017A2 (en) *	2011-07-21	2013-01-24	Alnylam Pharmaceuticals, Inc.	Compositions and methods for modifying the glycosylation of lysosomal storage disorder therapeutics
JP2014522105A (ja) *	2011-07-22	2014-08-28	インサイトフォトニックソリューションズ，インコーポレイテッド	波長連続及び規定された時間に対する波長掃引をレーザーから動的及び適応的に生成するシステム及び方法
CA2860085A1 (en)	2011-12-22	2013-06-27	Centogene Ip Gmbh	Combination of a compound having the ability to rearrange a lysosomal enzyme and ambroxol and/or a derivative of ambroxol
WO2013134530A1 (en)	2012-03-07	2013-09-12	Amicus Therapeutics, Inc.	High concentration alpha-glucosidase compositions for the treatment of pompe disease
US20150086530A1 (en)	2012-05-03	2015-03-26	Amicus Therapeutics, Inc.	Dosing regimens for the treatment of pompe disease
US20150147309A1 (en)	2012-06-06	2015-05-28	Fondazione Telethon	Allosteric chaperones and uses thereof
TWI529396B (zh)	2014-07-18	2016-04-11	Mpi Corp	Probe card and its transfer circuit board and signal feed structure
KR102741048B1 (ko)	2014-09-30	2024-12-11	아미쿠스 세라퓨틱스, 인코포레이티드	개선된 탄수화물을 가지는 고도로 강력한 산성 알파-글루코시다제

2015
- 2015-09-30 KR KR1020227035610A patent/KR102741048B1/ko active Active
- 2015-09-30 MX MX2017003989A patent/MX388241B/es unknown
- 2015-09-30 PE PE2017000507A patent/PE20170906A1/es unknown
- 2015-09-30 KR KR1020177011346A patent/KR102306577B1/ko active Active
- 2015-09-30 FI FIEP23191307.0T patent/FI4273241T3/fi active
- 2015-09-30 LT LTEP23191307.0T patent/LT4273241T/lt unknown
- 2015-09-30 FI FIEP15845664.0T patent/FI3201320T3/fi active
- 2015-09-30 TN TN2017000082A patent/TN2017000082A1/en unknown
- 2015-09-30 EA EA201790724A patent/EA038986B1/ru unknown
- 2015-09-30 SG SG11201702114TA patent/SG11201702114TA/en unknown
- 2015-09-30 HR HRP20250058TT patent/HRP20250058T1/hr unknown
- 2015-09-30 HU HUE15845664A patent/HUE064629T2/hu unknown
- 2015-09-30 PT PT158456640T patent/PT3201320T/pt unknown
- 2015-09-30 KR KR1020217030450A patent/KR102455814B1/ko active Active
- 2015-09-30 DK DK15845664.0T patent/DK3201320T5/da active
- 2015-09-30 CR CR20170107A patent/CR20170107A/es unknown
- 2015-09-30 ES ES23191307T patent/ES3017134T3/es active Active
- 2015-09-30 SG SG10202003753PA patent/SG10202003753PA/en unknown
- 2015-09-30 WO PCT/US2015/053252 patent/WO2016054231A1/en not_active Ceased
- 2015-09-30 CN CN201580052512.5A patent/CN107075468B/zh active Active
- 2015-09-30 CN CN202111483006.5A patent/CN114540327A/zh active Pending
- 2015-09-30 CA CA2961762A patent/CA2961762C/en active Active
- 2015-09-30 MY MYPI2017000365A patent/MY186336A/en unknown
- 2015-09-30 KR KR1020247040492A patent/KR20250004926A/ko active Pending
- 2015-09-30 EP EP23191307.0A patent/EP4273241B1/en active Active
- 2015-09-30 RS RS20250154A patent/RS66510B1/sr unknown
- 2015-09-30 AU AU2015325028A patent/AU2015325028B2/en active Active
- 2015-09-30 DK DK23191307.0T patent/DK4273241T3/da active
- 2015-09-30 EP EP24197546.5A patent/EP4455283A3/en active Pending
- 2015-09-30 US US15/515,808 patent/US10208299B2/en active Active
- 2015-09-30 HR HRP20240041TT patent/HRP20240041T1/hr unknown
- 2015-09-30 HU HUE23191307A patent/HUE070443T2/hu unknown
- 2015-09-30 LT LTEPPCT/US2015/053252T patent/LT3201320T/lt unknown
- 2015-09-30 PL PL23191307.0T patent/PL4273241T3/pl unknown
- 2015-09-30 JP JP2017516917A patent/JP6851964B2/ja active Active
- 2015-09-30 IL IL307587A patent/IL307587A/en unknown
- 2015-09-30 ES ES15845664T patent/ES2967620T3/es active Active
- 2015-09-30 IL IL289383A patent/IL289383B2/en unknown
- 2015-09-30 SI SI201532053T patent/SI4273241T1/sl unknown
- 2015-09-30 PT PT231913070T patent/PT4273241T/pt unknown
- 2015-09-30 SM SM20240010T patent/SMT202400010T1/it unknown
- 2015-09-30 EP EP15845664.0A patent/EP3201320B1/en active Active
- 2015-09-30 SM SM20250074T patent/SMT202500074T1/it unknown
- 2015-09-30 PL PL15845664.0T patent/PL3201320T3/pl unknown
- 2015-09-30 CA CA3228032A patent/CA3228032A1/en active Pending
- 2015-09-30 SI SI201531983T patent/SI3201320T1/sl unknown
- 2015-09-30 RS RS20240027A patent/RS65066B1/sr unknown
- 2015-09-30 BR BR112017005810A patent/BR112017005810A2/pt not_active Application Discontinuation
2017
- 2017-03-10 PH PH12017500455A patent/PH12017500455A1/en unknown
- 2017-03-14 IL IL251152A patent/IL251152B/en active IP Right Grant
- 2017-03-20 ZA ZA2017/01945A patent/ZA201701945B/en unknown
- 2017-03-20 DO DO2017000079A patent/DOP2017000079A/es unknown
- 2017-03-23 CO CONC2017/0002776A patent/CO2017002776A2/es unknown
- 2017-03-27 MX MX2021014565A patent/MX2021014565A/es unknown
- 2017-03-27 CL CL2017000722A patent/CL2017000722A1/es unknown
- 2017-03-28 EC ECIEPI201719103A patent/ECSP17019103A/es unknown
- 2017-03-28 SV SV2017005416A patent/SV2017005416A/es unknown
- 2017-03-28 NI NI201700039A patent/NI201700039A/es unknown
2019
- 2019-01-18 US US16/252,505 patent/US10961522B2/en active Active
- 2019-03-19 ZA ZA2019/01690A patent/ZA201901690B/en unknown
2020
- 2020-09-23 IL IL277529A patent/IL277529B/en unknown
- 2020-09-25 JP JP2020161470A patent/JP7225176B2/ja active Active
2021
- 2021-02-23 US US17/249,175 patent/US11753632B2/en active Active
2022
- 2022-02-04 US US17/665,179 patent/US11591583B2/en active Active
- 2022-05-24 AU AU2022203498A patent/AU2022203498B2/en active Active
2023
- 2023-02-08 JP JP2023017964A patent/JP2023078118A/ja active Pending
- 2023-02-17 US US18/111,321 patent/US20230203465A1/en active Pending
2024
- 2024-01-10 CY CY20241100016T patent/CY1126544T1/el unknown
- 2024-03-28 FR FR24C1012C patent/FR24C1012I1/fr active Active
- 2024-04-02 LT LTPA2024509C patent/LTPA2024509I1/lt unknown
- 2024-04-02 CY CY2024009C patent/CY2024009I2/el unknown
- 2024-04-02 HU HUS2400007C patent/HUS2400007I1/hu unknown
- 2024-04-03 FI FIC20240010C patent/FIC20240010I1/fi unknown
2025
- 2025-01-17 US US19/028,827 patent/US20260015600A1/en active Pending
- 2025-02-17 AU AU2025201108A patent/AU2025201108A1/en active Pending
- 2025-05-21 FI FIC20250020C patent/FIC20250020I1/fi unknown
- 2025-05-23 NO NO2025023C patent/NO2025023I1/no unknown
- 2025-05-23 FR FR25C1019C patent/FR25C1019I1/fr active Active
- 2025-06-02 LT LTPA2025521C patent/LTPA2025521I1/lt unknown
- 2025-06-03 HU HUS2500025C patent/HUS2500025I1/hu unknown

Also Published As

Publication number	Publication date
US20210261935A1 (en)	2021-08-26
IL277529A (en)	2020-11-30
SG10202003753PA (en)	2020-05-28
FIC20250020I1 (fi)	2025-05-21
MX2017003989A (es)	2017-07-07
HRP20240041T1 (hr)	2024-03-29
IL307587A (en)	2023-12-01
CY2024009I1 (el)	2025-05-09
US20220162578A1 (en)	2022-05-26
US20170298335A1 (en)	2017-10-19
CN107075468A (zh)	2017-08-18
CO2017002776A2 (es)	2017-08-10
JP6851964B2 (ja)	2021-03-31
AU2022203498A1 (en)	2022-06-09
IL251152A0 (en)	2017-04-30
DK3201320T3 (da)	2024-01-08
HUE070443T2 (hu)	2025-06-28
LT3201320T (lt)	2024-01-25
KR20220146662A (ko)	2022-11-01
CN114540327A (zh)	2022-05-27
EP3201320A4 (en)	2018-03-14
US20190276812A1 (en)	2019-09-12
ZA201901690B (en)	2022-06-29
EA201790724A1 (ru)	2017-08-31
CY1126544T1 (el)	2025-05-09
PT4273241T (pt)	2025-02-24
US11753632B2 (en)	2023-09-12
JP2017537604A (ja)	2017-12-21
RS66510B1 (sr)	2025-03-31
IL289383A (en)	2022-02-01
MX388241B (es)	2025-03-19
KR20250004926A (ko)	2025-01-08
AU2015325028A1 (en)	2017-03-16
CA2961762A1 (en)	2016-04-07
CA3228032A1 (en)	2016-04-07
SI3201320T1 (sl)	2024-02-29
WO2016054231A1 (en)	2016-04-07
LTPA2025521I1 (lt)	2025-06-25
RS65066B1 (sr)	2024-02-29
SMT202500074T1 (it)	2025-03-12
NZ768484A (en)	2024-05-31
SV2017005416A (es)	2017-08-08
EA038986B1 (ru)	2021-11-18
IL289383B1 (en)	2023-11-01
MY186336A (en)	2021-07-13
DK3201320T5 (da)	2024-10-14
KR20170063837A (ko)	2017-06-08
PH12017500455A1 (en)	2017-07-31
IL289383B2 (en)	2024-03-01
HUS2500025I1 (hu)	2025-06-28
PL3201320T3 (pl)	2024-03-18
FI3201320T3 (fi)	2024-01-08
AU2015325028B2 (en)	2022-02-24
ES2967620T3 (es)	2024-05-03
HUS2400007I1 (hu)	2024-04-28
BR112017005810A2 (pt)	2018-02-27
US10208299B2 (en)	2019-02-19
EP4273241A3 (en)	2024-01-24
SI4273241T1 (sl)	2025-03-31
KR102455814B1 (ko)	2022-10-18
PL4273241T3 (pl)	2025-04-14
ZA201701945B (en)	2019-06-26
US10961522B2 (en)	2021-03-30
JP2023078118A (ja)	2023-06-06
EP4273241A2 (en)	2023-11-08
US11591583B2 (en)	2023-02-28
CY2024009I2 (el)	2025-05-09
IL251152B (en)	2021-06-30
EP4273241B1 (en)	2024-12-04
NO2025023I1 (no)	2025-05-23
HUE064629T2 (hu)	2024-04-28
CN107075468B (zh)	2021-12-24
DK4273241T3 (da)	2025-02-24
FIC20240010I1 (fi)	2024-04-03
AU2022203498B2 (en)	2025-03-13
KR102741048B1 (ko)	2024-12-11
EP3201320A1 (en)	2017-08-09
US20260015600A1 (en)	2026-01-15
LTPA2024509I1 (lt)	2024-04-25
CR20170107A (es)	2017-09-01
US20230203465A1 (en)	2023-06-29
SG11201702114TA (en)	2017-04-27
KR102306577B1 (ko)	2021-10-01
ES3017134T3 (en)	2025-05-12
EP4455283A2 (en)	2024-10-30
TN2017000082A1 (en)	2018-07-04
MX2021014565A (es)	2022-01-11
ECSP17019103A (es)	2017-06-30
EP4455283A3 (en)	2025-01-22
FI4273241T3 (fi)	2025-03-08
HRP20250058T1 (hr)	2025-03-28
AU2025201108A1 (en)	2025-03-06
PE20170906A1 (es)	2017-07-12
SMT202400010T1 (it)	2024-03-13
FR24C1012I1 (fr)	2024-05-24
CA2961762C (en)	2024-03-05
FR25C1019I1 (fr)	2025-08-01
NZ729507A (en)	2021-10-29
EP3201320B1 (en)	2023-10-11
JP2021011489A (ja)	2021-02-04
JP7225176B2 (ja)	2023-02-20
PT3201320T (pt)	2024-01-12
CL2017000722A1 (es)	2017-12-15
DOP2017000079A (es)	2017-05-31
IL277529B (en)	2022-02-01
NI201700039A (es)	2018-01-05
KR20210118977A (ko)	2021-10-01

Publication	Publication Date	Title
CY2024009I1 (el)	2025-05-09	Εξαιρετικα ισχυρη οξινη αλφα-γλυκοσιδαση με ενισχυμενους υδατανθρακες
DK3218519T3 (da)	2020-12-21	Multipass-sekvensering
FR3006466B3 (fr)	2015-10-30	.
PL3151327T3 (pl)	2019-11-29	Roztwór elektrolitu
EP3227659C0 (en)	2025-05-14	THAWING PROCESSES
DE112015005628A5 (de)	2017-09-07	Steckverbinder
FR3023988B3 (fr)	2016-07-22	.
DE202014104222U8 (de)	2016-03-17	Steckverbinder
FR3001302B1 (fr)	2016-01-22	.
DK3348191T3 (da)	2022-05-23	Kapnometer
CL2015001184S1 (es)	2015-12-18	Conector
FI20145173L (fi)	2015-08-22	Esikammiojärjestely
DK2921760T3 (da)	2019-10-21	Afstandsstykke.
FR3001303B1 (fr)	2015-07-31	.
BR302014000477S1 (pt)	2014-11-25	Configuração aplicada em solado
ES1105680Y (es)	2014-07-01	Baliza avifauna.
ES2654061T8 (es)	2018-05-10	Conector
BR302014000622S1 (pt)	2014-09-23	Configuração aplicada em prendedor.
TH1601003915A (th)	2017-03-23	ตัวเชื่อมต่อ
ES1113105Y (es)	2014-09-09	Estructura metalica.
TH1501006062A (th)	2017-06-08	โครงสร้างที่ผ่านการชุบเงิน
BR302014002339S1 (pt)	2015-07-07	Configuração aplicada em suporte
BR302014002138S1 (pt)	2015-07-07	Configuração aplicada em suporte
BR302014002137S1 (pt)	2015-07-07	Configuração aplicada em suporte
BR302014001854S1 (pt)	2015-06-16	Configuração aplicada em bolsa